StockNews.com assumed coverage on shares of TG Therapeutics (NASDAQ:TGTX – Free Report) in a report released on Saturday morning. The firm issued a hold rating on the biopharmaceutical company’s stock. Several other equities research analysts also recently commented on the company. JPMorgan Chase & Co. dropped their target price on TG Therapeutics from $34.00 to […]
Cantor Fitzgerald reiterated their overweight rating on shares of Ambrx Biopharma (NYSE:AMAM – Free Report) in a research note issued to investors on Wednesday, Benzinga reports. Cantor Fitzgerald currently has a $25.00 price target on the stock. A number of other research analysts have also recently commented on the company. Royal Bank of Canada began […]
TG Therapeutics (NASDAQ:TGTX – Get Free Report) had its price objective lowered by equities research analysts at JPMorgan Chase & Co. from $34.00 to $22.00 in a research note issued to investors on Monday, Benzinga reports. The firm presently has an “overweight” rating on the biopharmaceutical company’s stock. JPMorgan Chase & Co.‘s price objective would […]
Ambrx Biopharma Inc. (NYSE:AMAM – Get Free Report) has received an average recommendation of “Moderate Buy” from the six ratings firms that are currently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average twelve-month price […]
TG Therapeutics (NASDAQ:TGTX – Free Report) had its price objective lifted by HC Wainwright from $34.00 to $41.00 in a research report released on Tuesday morning, Benzinga reports. They currently have a buy rating on the biopharmaceutical company’s stock. HC Wainwright also issued estimates for TG Therapeutics’ Q3 2023 earnings at ($0.19) EPS, Q4 2023 […]